Compare Merck & Co., Inc. (MRK) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vital Farms Inc — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Vital Farms Inc trades at $13.16 (market cap $590.45M). The key difference: Merck & Co., Inc. is far larger — about 520.4× Vital Farms Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| MRK | VITL | |
|---|---|---|
Market Cap | $307.25B | $590.45M |
Sector | Health | Consumer Staples |
52-Week High | $129.52 | $52.41 |
52-Week Low | $77.60 | $8.28 |
Enterprise Value | $350.66B | $593.26M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Vital Farms (VITL) trades at $13.76, up 1.55% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 15.44% ROE and trades at a modest P/E of 13.25. Recent earnings have been mixed, with a Q3 2025 beat but Q1 2026 miss, while analyst sentiment remains positive with 56% buy ratings. Net cash flow is negative due to significant investing activities, and a class action lawsuit filed in May 2026 adds legal overhang.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term performance hinges on reversing negative earnings surprises and managing legal risks. The consensus price target of $13.50 suggests limited upside from current levels, with execution on revenue growth and margin stabilization key to driving shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
